These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

354 related articles for article (PubMed ID: 19487159)

  • 1. Strategies for recruiting and targeting dendritic cells for optimizing HIV vaccines.
    Ahlers JD; Belyakov IM
    Trends Mol Med; 2009 Jun; 15(6):263-74. PubMed ID: 19487159
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Strategies for optimizing targeting and delivery of mucosal HIV vaccines.
    Ahlers JD; Belyakov IM
    Eur J Immunol; 2009 Oct; 39(10):2657-69. PubMed ID: 19609978
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systemic mobilization of antigen presenting cells, with a chimeric Flt-3 and G-CSF receptor agonist, during immunization of Macaca mulatta with HIV-1 antigens is insufficient to modulate immune responses or vaccine efficacy.
    Koopman G; Mortier D; Niphuis H; Farese AM; Kahn LE; Mann D; Wagner R; MacVittie TJ; Woulfe SL; Heeney JL
    Vaccine; 2005 Jul; 23(33):4195-202. PubMed ID: 15896883
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Innate gamma/delta T-cells during HIV infection: Terra relatively Incognita in novel vaccination strategies?
    Agrati C; D'Offizi G; Gougeon ML; Malkovsky M; Sacchi A; Casetti R; Bordoni V; Cimini E; Martini F
    AIDS Rev; 2011; 13(1):3-12. PubMed ID: 21412385
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HIV-1 Tat addresses dendritic cells to induce a predominant Th1-type adaptive immune response that appears prevalent in the asymptomatic stage of infection.
    Fanales-Belasio E; Moretti S; Fiorelli V; Tripiciano A; Pavone Cossut MR; Scoglio A; Collacchi B; Nappi F; Macchia I; Bellino S; Francavilla V; Caputo A; Barillari G; Magnani M; Laguardia ME; Cafaro A; Titti F; Monini P; Ensoli F; Ensoli B
    J Immunol; 2009 Mar; 182(5):2888-97. PubMed ID: 19234184
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The role of dendritic cells in the infection by HIV and HCV].
    Belmonte L; Parodi C; Bare P; Baston M; Bracco MM; Ruibal-Ares B
    Medicina (B Aires); 2007; 67(1):63-70. PubMed ID: 17408026
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modulating vaccine responses with dendritic cells and Toll-like receptors.
    Pulendran B
    Immunol Rev; 2004 Jun; 199():227-50. PubMed ID: 15233738
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dendritic cell biology.
    Granucci F; Foti M; Ricciardi-Castagnoli P
    Adv Immunol; 2005; 88():193-233. PubMed ID: 16227091
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dendritic cell-based cancer immunotherapies.
    Fujii S; Takayama T; Asakura M; Aki K; Fujimoto K; Shimizu K
    Arch Immunol Ther Exp (Warsz); 2009; 57(3):189-98. PubMed ID: 19479202
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of Toll-like receptors and C-type lectins for vaccination against Candida albicans.
    Ferwerda G; Netea MG; Joosten LA; van der Meer JW; Romani L; Kullberg BJ
    Vaccine; 2010 Jan; 28(3):614-22. PubMed ID: 19887129
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dendritic cell subsets and toll-like receptors.
    Hochrein H; O'Keeffe M
    Handb Exp Pharmacol; 2008; (183):153-79. PubMed ID: 18071659
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term HIV-specific responses and delayed resumption of antiretroviral therapy after peptide immunization targeting dendritic cells.
    Kran AM; Sørensen B; Sommerfelt MA; Nyhus J; Baksaas I; Kvale D
    AIDS; 2006 Feb; 20(4):627-30. PubMed ID: 16470131
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The role of toll-like receptors in viral infections: HIV-1 as a model].
    Hernández JC; Montoya CJ; Urcuqui-Inchima S
    Biomedica; 2007 Jun; 27(2):280-93. PubMed ID: 17713639
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanisms of dendritic cell-based vaccination against infection.
    Fajardo-Moser M; Berzel S; Moll H
    Int J Med Microbiol; 2008 Jan; 298(1-2):11-20. PubMed ID: 17719274
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Dendritic cell vaccine is a hope for alternative treatment of HIV infection].
    Kahl U
    Lakartidningen; 2003 Jun; 100(25):2224. PubMed ID: 12872511
    [No Abstract]   [Full Text] [Related]  

  • 16. Targeting glycan modified OVA to murine DC-SIGN transgenic dendritic cells enhances MHC class I and II presentation.
    Singh SK; Stephani J; Schaefer M; Kalay H; García-Vallejo JJ; den Haan J; Saeland E; Sparwasser T; van Kooyk Y
    Mol Immunol; 2009 Dec; 47(2-3):164-74. PubMed ID: 19818504
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunostimulatory combinations: designing the next generation of vaccine adjuvants.
    Kornbluth RS; Stone GW
    J Leukoc Biol; 2006 Nov; 80(5):1084-102. PubMed ID: 16931603
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Innate control of adaptive immunity: dendritic cells and beyond.
    Lee HK; Iwasaki A
    Semin Immunol; 2007 Feb; 19(1):48-55. PubMed ID: 17276695
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rates of HIV immune escape and reversion: implications for vaccination.
    Davenport MP; Loh L; Petravic J; Kent SJ
    Trends Microbiol; 2008 Dec; 16(12):561-6. PubMed ID: 18964018
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of cytokines and chemokines in the regulation of innate immunity and HIV infection.
    Alfano M; Poli G
    Mol Immunol; 2005 Feb; 42(2):161-82. PubMed ID: 15488606
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.